Skip to Main Content
Skip Nav Destination

Intravenous Acyclovir Shortage Recommendations for Pediatrics

May 3, 2021

Antiviral Recommendations for Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV) Infections in Hospitalized Pediatric Patients during the Intravenous Acyclovir Shortage

Originally posted March 2009; reviewed May 2021


Antiviral Recommendations for Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV) Infections in Hospitalized Pediatric Patients during the Intravenous Acyclovir Shortage

These recommendations should be instituted in consultation with a pediatric infectious disease practitioner.
Until the national shortage is resolved, intravenous (IV) acyclovir should be reserved for the following priority conditions:

  • Neonates with proven HSV disease (20mg/kg/dose every 8 hours)
  • Pregnant women
  • Individuals with herpes simplex encephalitis.

 

Alternative regimens to intravenous acyclovir (when supplies are depleted) and alternatives for non-priority conditions are outlined below:

Condition 1st line therapy 2nd line therapy
*Herpes simplex encephalitis and *suspected/proven neonatal HSV disease IV ganciclovir
≤90 days old: 6mg/kg every 12 hrs
>90 days old: 5mg/kg every 12 hrs
IV foscarnet
60mg/kg every 12 hrs
Skin recurrences following neonatal HSV disease (without CNS involvement at the time)
[NOTE: with CNS involvement, see above recommendations for intravenous alternatives*]
Oral/ng tube acyclovir 20 mg/kg/dose four times a day;
[max per dose: 800 mg (3200 mg/day)]
**Oral/ng tube valacyclovir
20 mg/kg/dose three times a day;
[max per dose: 1000 mg (3000 mg/day)]
HSV gingivostomatitis
or
HSV infection in an immunocompetent host
or
Varicella infection in an immunocompetent host
**Oral/ng tube valacyclovir 20 mg/kg/dose three times a day;
[max per dose: 1000 mg (3000 mg/day)]
Oral/ng tube acyclovir
20 mg/kg/dose four times a day;
[max per dose: 800 mg (3200 mg/day)]
Zoster infection in an immunocompetent host **Oral/ng tube valacyclovir 20 mg/kg/dose three times a day;
[max per dose: 1000 mg (3000 mg/day)]
Oral/ng tube acyclovir
20 mg/kg/dose five times a day;
[max per dose: 800 mg (4000 mg/day)]
Treatment of HSV / VZV infection in immunocompromised hosts and those unable to take oral acyclovir or valacyclovir IV ganciclovir
≤90 days old: 6mg/kg every 12 hrs
>90 days old: 5mg/kg every 12 hrs
IV foscarnet
60mg/kg every 12 hrs
(may used as first line therapy if concerned about neutropenia and less concerned about renal function)

*Until the national shortage is resolved, IV acyclovir should be reserved for the following priority conditions: 1) Neonates with proven HSV disease (20mg/kg/dose every 8 hours); 2) Pregnant women; 3) Individuals with herpes simplex encephalitis.

**limited data exist in infants less than 3 months of age.

Drug Side Effect Monitoring:
Ganciclovir – monitor CBC d/p and BMP
Foscarnet - monitor BMP with Ca, Mg, and P Table compiled by Natasha Halasa, MD, based upon the COID table published in March 2009 AAP News ("Ganciclovir may be used during intravenous acyclovir shortage," David W. Kimberlin, MD, FAAP). Table further modified based upon input by the NIAID Collaborative Antiviral Study Group investigators.

Close Modal

or Create an Account

Close Modal
Close Modal